Binding of Complement Factor H (fH) to Neisseria meningitidis Is Specific for Human fH and Inhibits Complement Activation by Rat and Rabbit Sera

被引:147
作者
Granoff, Dan M. [1 ]
Welsch, Jo Anne [1 ]
Ram, Sanjay [2 ]
机构
[1] Childrens Hosp Oakland, Res Inst, Ctr Immunobiol & Vaccine Dev, Oakland, CA 94609 USA
[2] Univ Massachusetts, Sch Med, Div Infect Dis & Immunol, Worcester, MA 01605 USA
关键词
MEMBRANE VESICLE VACCINES; MENINGOCOCCAL POLYSACCHARIDE VACCINE; B CAPSULAR POLYSACCHARIDE; TOXOID CONJUGATE VACCINE; BACTERICIDAL ACTIVITY; GROUP-C; PROTECTIVE ACTIVITY; NEW-ZEALAND; MONOCLONAL-ANTIBODIES; CANDIDATE VACCINE;
D O I
10.1128/IAI.01191-08
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Complement factor H (fH), a molecule that downregulates complement activation, binds to Neisseria meningitidis and increases resistance to serum bactericidal activity. We investigated the species specificity of fH binding and the effect of human fH on downregulating rat ( relevant for animal models) and rabbit ( relevant for vaccine evaluation) complement activation. Binding to N. meningitidis was specific for human fH ( low for chimpanzee fH and not detected with fH from lower primates). The addition of human fH decreased rat and rabbit C3 deposition on the bacterial surface and decreased group C bactericidal titers measured with rabbit complement 10- to 60-fold in heat-inactivated sera from human vaccinees. Administration of human fH to infant rats challenged with group B strain H44/76 resulted in an fH dose-dependent increase in CFU/ml of bacteria in blood 8 h later (P < 0.02). At the highest fH dose, 50 mu g/rat, the geometric mean number of CFU per ml was higher than that in control animals (1,050 versus 43 [P < 0.005]). The data underscore the importance of binding of human fH for survival of N. meningitidis in vitro and in vivo. The species specificity of binding of human fH adds another mechanism toward our understanding of why N. meningitidis is strictly a human pathogen.
引用
收藏
页码:764 / 769
页数:6
相关论文
共 51 条
[1]   Validation of serological correlate of protection for meningococcal C conjugate vaccine by using efficacy estimates from postlicensure surveillance in England [J].
Andrews, N ;
Borrow, R ;
Miller, E .
CLINICAL AND DIAGNOSTIC LABORATORY IMMUNOLOGY, 2003, 10 (05) :780-786
[2]   PROTECTIVE EFFICACY OF MOUSE SERUM TO THE N-PROPIONYL DERIVATIVE OF MENINGOCOCCAL GROUP-B POLYSACCHARIDE [J].
ASHTON, FE ;
RYAN, JA ;
MICHON, F ;
JENNINGS, HJ .
MICROBIAL PATHOGENESIS, 1989, 6 (06) :455-458
[3]  
Balmer Paul, 2004, Expert Rev Vaccines, V3, P77, DOI 10.1586/14760584.3.1.77
[4]   Meningococcal surrogates of protection - serum bactericidal antibody activity [J].
Borrow, R ;
Balmer, P ;
Miller, E .
VACCINE, 2005, 23 (17-18) :2222-2227
[5]   Serological basis for use of meningococcal serogroup C conjugate vaccines in the United Kingdom: Reevaluation of correlates of protection [J].
Borrow, R ;
Andrews, N ;
Goldblatt, D ;
Miller, E .
INFECTION AND IMMUNITY, 2001, 69 (03) :1568-1573
[6]   ACTIVATION OF ALTERNATIVE COMPLEMENT PATHWAY DUE TO RESISTANCE OF ZYMOSAN-BOUND AMPLIFICATION CONVERTASE TO ENDOGENOUS REGULATORY MECHANISMS [J].
FEARON, DT ;
AUSTEN, KF .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1977, 74 (04) :1683-1687
[7]   HUMAN IMMUNITY TO MENINGOCOCCUS .I. ROLE OF HUMORAL ANTIBODIES [J].
GOLDSCHNEIDER, I ;
GOTSCHLICH, EC ;
ARTENSTEIN, MS .
JOURNAL OF EXPERIMENTAL MEDICINE, 1969, 129 (06) :1307-+
[8]   HUMAN IMMUNITY TO MENINGOCOCCUS .2. DEVELOPMENT OF NATURAL IMMUNITY [J].
GOLDSCHNEIDER, I ;
GOTSCHLICH, EC ;
ARTENSTEIN, MS .
JOURNAL OF EXPERIMENTAL MEDICINE, 1969, 129 (06) :1327-+
[9]   Persistence of group C anticapsular antibodies two to three years after immunization with an investigational quadrivalent Neisseria meningitidis-diphtheria toxoid conjugate vaccine [J].
Granoff, DM ;
Morgan, A ;
Welsch, JA .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2005, 24 (02) :132-136
[10]   Factor H, a regulator of complement activity, is a major determinant of meningococcal disease susceptibility in UK Caucasian patients [J].
Haralambous, Elene ;
Dolly, Saoirse O. ;
Hibberd, Martin L. ;
Litt, David J. ;
Udalova, Irina A. ;
O'Dwyer, Cliona ;
Langford, Paul R. ;
Kroll, J. Simon ;
Levin, Michael .
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2006, 38 (09) :764-771